ReviewAmerican journal of translational research2025
Mechanisms and therapeutic potential of hyperbaric oxygen inducing autophagy in cerebral ischemia-reperfusion injury.
Review in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Intra-Arterial Selective Hypothermic Human Serum Albumin Perfusion Attenuates Cerebral Ischemia-Reperfusion Injury.Translational stroke research · 2026Article
- Exercise Improves Mitochondrial Homeostasis: A Potential Neuroprotective Strategy for Ischemic Stroke.Antioxidants (Basel, Switzerland) · 2026Review
- Non-invasive neuroregulation techniques applied to patients with consciousness disorders: a narrative review.Frontiers in human neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral ischemia-reperfusion injury (CIRI) is a complex pathological process involving oxidative stress, inflammation, and dysregulated autophagy. Hyperbaric oxygen therapy (HBO) has emerged as a promising intervention that mitigates neuronal injury by modulating autophagy. This review summarizes current evidence on the mechanisms of HBO through the AMPK-mTOR, HIF-1α-mTOR, and PI3K-AKT pathways, emphasizing its dual role in either promoting cell survival or exacerbating injury depending on autophagic flux. Preclinical studies demonstrate that HBO upregulates LC3-II and Beclin-1 while downregulating p62, indicating enhanced autophagy, whereas clinical trials (e.g., OPENS-2) suggest synergistic effects when combined with endovascular therapy. However, challenges remain regarding the lack of standardized biomarkers and optimal treatment parameters. Future research should focus on integrating HBO with specific autophagy modulators and conducting large-scale randomized controlled trials to validate its therapeutic potential in CIRI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.